ArticleJournal of cheminformatics2026
Sequence-based drug-target binding site pre-training enables cryptic pocket detection and improves binding affinity and kinetics prediction.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
Accurately characterizing protein-ligand binding, such as binding site, affinity and kinetics, is critical for accelerating drug discovery. However, many existing computational methods face key limitations, including insufficient integration of comprehensive databases, inadequate representation of protein structural dynamics, and incomplete modeling of microscale protein-ligand interactions. To address these challenges, we introduce ProMoNet, a sequence-based pre-training and fine-tuning framework to enhance the prediction of protein-ligand binding characteristics. ProMoNet leverages protein and molecular foundation models to expand data coverage and enhance diversity. It also introduces a pre-training strategy based on protein-ligand binding site prediction, which bridges protein- and ligand-level representations to support downstream prediction tasks involving protein-ligand complexes. Our pre-training module effectively models microscale protein-ligand interactions and captures the dynamic nature of proteins, including binding site crypticity, without relying on 3-dimensional structural inputs. Notably, this module surpasses or matches state-of-the-art structure-based methods in identifying exposed and cryptic binding sites while maintaining high efficiency. Our fine-tuning module then efficiently transfers the pre-trained knowledge to downstream tasks such as binding affinity and binding kinetics prediction, achieving superior performance. The combination of ProMoNet's strong performance and demonstrated efficiency across multiple tasks highlights its potential for broad applications in drug discovery.Scientific Contribution We propose ProMoNet, a sequence-based pre-training and fine-tuning framework for protein-ligand binding characteristic prediction, where protein-ligand binding site prediction is introduced as a pre-training strategy to bridge independent protein- and ligand-level representations for downstream complex-level tasks. We design two dedicated modules, including a pre-training module that models microscale protein-ligand interactions and captures protein dynamics, as well as a fine-tuning module that efficiently integrates the pre-trained representations for downstream tasks. Even compared to structure-based methods, ProMoNet matches state-of-the-art performance in exposed and cryptic binding site identification and delivers superior results in binding affinity and kinetics prediction, making it a promising tool for drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.